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Abstract
Background: Intravenous (IV) artesunate is the treatment of choice for severe malaria. In Europe, however, no
GMP-manufactured product is available and treatment data in European travellers are scarce. Fortunately,
artesunate became available in the Netherlands and Belgium through a named patient programme. This is the
largest case series of artesunate treated patients with severe malaria in Europe.
Methods: Hospitalized patients treated with IV artesunate between November 2007 and December 2010 in the
Netherlands and Belgium were retrospectively evaluated. Patient characteristics, treatment and clinical outcome
were recorded on a standardized form and mortality, parasite clearance times and the occurrence of adverse
events were evaluated.
Results: Of the 68 treated patients, including 55 with severe malaria, two patients died (2/55 = 3.6%). The mean
time to 50% parasite clearance (PCT50), 90% and 99% were 4.4 hours (3.9 - 5.2), 14.8 hours (13.0 - 17.2), and 29.5
hours (25.9 - 34.4) respectively. Artesunate was well tolerated. However, an unusual form of haemolytic anaemia
was observed in seven patients. The relationship with artesunate remains uncertain.
Conclusions: Data from the named patient programme demonstrate that IV artesunate is effective and well-
tolerated in European travellers lacking immunity. However, increased attention needs to be paid to the possible
development of haemolytic anaemia 2-3 weeks after start of treatment.
Treatment of IV artesunate should be limited to the period that IV treatment is required and should be followed
by a full oral course of an appropriate anti-malarial drug.
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Background
Intravenous (IV) quinine or a mixture of four cinchona
alkaloids (Quinimax)
® were, for many years, the only
available drugs in Europe for the treatment of imported
severe malaria. In the US, where quinine is not available,
quinidine was used for this indication. Quinine IV has a
narrow therapeutic window with significant adverse
effects, such as hypotension, cardiac arrhythmia, acoustic
problems with temporary deafness and hypoglycaemia.
The arrhythmogenic effects of quinidine are even more
pronounced.
In the early 1970s, artemisinin, isolated from the Chi-
nese herb Qinghao (sweetworm or Artemisia annua),
was found to be a very potent anti-malarial agent. Arte-
misinin drugs have a broad stage specificity of action
against all of the erythrocytic stages of the parasite,
induce fast parasite clearance and prevent maturation
and sequestration of parasites [1]. For parenteral admin-
istration, semi-synthetic derivatives of artemisinin were
developed with even higher intrinsic activity than the
parent compound. The water-soluble sodium artesunate
was developed for IV administration.
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in endemic regions showed that, in both adults and chil-
dren, treatment with IV artesunate is superior to IV qui-
nine [2,3]. The mortality rate among quinine treated
patients was 22% and 10.9% in the SEAQUAMAT and
AQUAMAT studies respectively; for artesunate this was
15% and 8.5%, a significant reduction of 35% and 22.5%
respectively. Patients with hyperparasitaemia (> 10% of
RBC) had a significantly greater treatment effect with
artesunate than non-hyperparasitaemic patients. Artesu-
nate was also better tolerated, safer and easier to use
than quinine. The life-saving benefit of artesunate in
severe malaria was recognized by the WHO in 2006, and
IV artesunate is since then the treatment of choice for
severe falciparum malaria [4].
The mortality of severe malaria among European
patients is lower than in endemic countries. A recent
study by Bruneel and colleagues [5] showed a mortality
rate of 10.5% among French patients with severe malaria
treated with IV quinine. Artesunate has not yet been stu-
died widely in European travellers with severe malaria,
with no or partial immunity, although some case series
have been described recently [6,7].
The main barrier for the use of IV artesunate in Europe
and the US is the absence of a product that is manufac-
tured under Good Manufacturing Practices (GMP). The
Chinese manufacturer (Guilin Pharmaceutical Company
Ltd., Shanghai, China) of the product that was also used
in the SEAQUAMAT and AQUAMAT studies recently
improved the production process, with support of the
Medicine for Malaria Venture (MMV). This convinced
the WHO to list it as prequalified medicinal product [8].
This ensures that manufacturing of the product has been
evaluated and inspected by WHO and complies with
WHO requirements for essential drugs. Nevertheless,
this is not the same as GMP certification and in both the
EU and the US, IV artesunate does not have a market
authorization. A salient fact is that IV quinine is also not
registered in most industrialized countries, where it is
mainly available through extemporaneous preparation by
hospital pharmacies, and there is no IV quinine formula-
tion on the WHO list of prequalified medicinal products.
The Guilin IV artesunate product was made available
in the Netherlands following a specific article in the
Dutch Medicines Act. Import and quality control, based
on a monograph compliant to the European Pharmaco-
poeia and the United States Pharmacopoeia, is per-
formed by a Dutch company (ACE Pharmaceuticals
B.V., Zeewolde, the Netherlands), which distributes the
product under the trade name Malacef 60
®. Malacef
received an orphan designation (EU/3/07/430) by the
European Medicines Agency in February 2007. It is
available through a named patient programme. The pro-
duct, kept in emergency stock in the hospital pharmacy,
is prescribed to an individual patient accompanied by a
medical statement.
The objective of this study was to collect safety and
efficacy data of patients treated with IV artesunate. All
Dutch patients treated with IV artesunate since its intro-
duction in 2007 were traced and their data on safety and
efficacy were actively pursued. For Belgian patients, this
IV artesunate product became available in the beginning
of 2009 and data were collected from all traceable
patients.
Methods
Patients
All Dutch hospitalized patients, treated with IV artesu-
nate between November 2007 and December 2010 and
Belgian patients treated between January 2009 and
December 2010 and of whom data were available, were
traced.
Data collection
Through ACE Pharmaceuticals, the distributor of IV
artesunate, the addresses of the hospital pharmacies who
had ordered Malacef 60
® were obtained. The pharmacies
or infectious diseases specialists in those hospitals were
proactively contacted and through these the physicians
who had prescribed Malacef 60
®. They were requested to
fill out a standardized and anonymized case report form
(CRF) taking the data from the patients’ medical charts.
The following data were collected: demographic data and
travel-related history; clinical and laboratory data at pre-
sentation, the dosage of artesunate as well as that of
other administered anti-malarials and supportive therapy;
complications and outcome data, including malaria para-
site counts. In all hospitals parasite counts were per-
formed using Giemsa stained thick and thin blood
smears and density was either expressed as a percentage
of parasitized erythrocytes on a thin film or as the num-
ber of Plasmodium falciparum trophozoites per 100 white
blood cells on a thick film. The parasite load was calcu-
lated from these figures using the actual number of
WBCs or RBCs counted in the blood sample.
Definitions and criteria
T h i sw a sn o tap r o s p e c t i v et r i a la n ds ot h e r ew e r en o
fixed criteria for indication or patient selection. All cri-
teria were applied retrospectively for the purpose of
description and analysis of the data. This study did not
require approval from an ethics committee according to
the Dutch Medical Research Involving Human Subjects
Act (WMO).
The indication to administer IV artesunate, as well as
the criteria used to define severe malaria, were not
exactly similar in all hospitals. All used the WHO criteria
[9]: impaired consciousness, multiple convulsions (> 2
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oedema, circulatory collapse (systolic blood pressure < 70
mm Hg), haemoglobinuria, abnormal spontaneous bleed-
ing, hypoglycaemia (glucose < 2.2 mmol/l), metabolic
acidosis (plasma bicarbonate < 15 mmol/l, pH < 7.25),
severe anaemia (haemoglobin (Hb) < 3.1 mmol/l), hyper-
parasitaemia (> 5%), hyperlactataemia (lactate > 5 mmol/
l), renal impairment (serum creatinine > 265 μmol/l),
jaundice (serum bilirubin > 50 μmol/L). In most hospitals
malaria was considered severe with one or more of these
criteria; in one Belgian hospital artesunate was used only
for “very severe” malaria, with either parasitaemia > 10%
or three or more criteria of severity.
Data handling and statistical analysis
Since this is an observational study which is not easily
comparable to other studies, sample size calculation does
not lead to precise estimates of power. Therefore the
sample size of this study was mainly based on pragmatic
and logistic reasons but also on comparison to data given
in literature. For example, given the reduction of mortal-
ity in the SEAQUAMAT and AQUAMAT trials and the
mortality rate among European patients treated with qui-
nine [5], the mortality expected among European patients
with severe malaria, could be in the order of 7%. That
would imply inclusion of minimally 50 patients in this
study.
All extracted data were entered into a Microsoft Access
®
database and reviewed for inconsistencies. Routine statisti-
cal analyses were carried out using IBM SPSS Statistics 18
(IBM Inc, Chicago, IL). Descriptive statistics were used to
summarize baseline values and demographic data. Nor-
mality was assessed by the Kolmogorov-Smirnov test.
Population kinetic modelling is the method of choice for
unbalanced repeated measurements [10]. Parasite clear-
ance time (PCT)50%, PCT90%, and PCT99% were defined
as the time (in hours) to obtain a 50%, 90%, and 99%
reduction in parasite burden after start of artesunate treat-
ment. They were estimated by linear mixed effects popula-
tion modelling of the (mono-exponential) log-linear time
course of the parasitaemia using maximum likelihood
techniques. No additional covariates or factors were
included in the model. From this, the population mean
values of PCT 50% PCT90% and PCT99% were calculated.
The precision of the population estimates is given by their
95% confidence intervals.
Results
Patient characteristics
From November 2007 to December 2010, 68 patients with
imported malaria, hospitalized for parenteral treatment
with artesunate were traced; 52 in the Netherlands and 16
in Belgium. In all but two patients, malaria was acquired
in Africa. The majority (57%) of the patients were non-
immune travellers who had used no or inadequate malaria
chemoprophylaxis. Their clinical presentation is showed in
Table 1.
Plasmodium falciparum infection was diagnosed in 65
patients, one of these had a mixed infection with P. malar-
iae. Two patients were microscopically diagnosed with a
P. vivax monoinfection, and one with a P. ovale infection.
55 patients (81%) were classified with severe malaria (one
or more WHO criteria), four of whom had non severe
malaria on admission, but deteriorated to severe malaria
while receiving anti-malarial treatment other than IV arte-
sunate. The characteristics on admission are summarized
in Table 2.
Treatment
Most patients (84%) received the recommended dose of
2.4 mg/kg bodyweight of artesunate on admission and
12 and 24 hours later and then daily thereafter until
they were able to complete the treatment with a full
oral course of mainly atovaquone-proguanil (AP, Malar-
one
®) or artemether-lumefantrine (AL, Riamet
®), as
shown in Table 3.
Efficacy
All patients survived the acute malaria episode. Two of 55
patients (3.6%) with severe malaria died. The non severe
malaria patients all survived but were excluded from mor-
tality calculation. One patient died of an iatrogenic com-
plication (IV catheter related haemorrhage) 4 days after
complete parasite clearance; the other succumbed to a
suspected lung embolism 8 days after parasite clearance
(Table 4). 42 (62%) patients were admitted to the ICU
with a median ICU stay of 2 days (range 1-35 days). Med-
ian hospital stay was 4.5 days (range 1-76 days). Follow up
was performed in 49 patients (72%), with a median follow
up time of 23 days (range 6 - 203 days) after first day of
hospitalization. The mean values for PCT50%, PCT90%
and PCT99% were 4.4 hours (95% confidence interval 3.9
- 5.2 h), 14.8 hours (95% confidence interval 13.0 - 17.2 h),
and 29.5 hours (95% confidence interval 25.9 - 34.4 h)
respectively.
Safety
All reported complications are listed in Table 5. Most
recorded complications were compatible with the clinical
findings in severe malaria and already present before
initiation of IV artesunate. These complications were not
recorded as drug related. Noteworthy was the occurrence
of late onset haemolytic anaemia in six patients with
severe malaria (Table 6), characterized by increased reti-
culocyte counts, unconjugated bilirubin and lactate dehy-
drogenase and decreased haptoglobin and haemoglobin
( H b )v a l u e s .H bn a d i ro c c u r r e db e t w e e n7a n d3 1d a y s
after treatment initiation (Figure 1). In two patients,
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the other four there was complete parasite and fever
clearance. In five patients, the pattern of haemolysis was
characterized by a decrease of the Hb value or a failure of
the Hb value to recover during week 2. The remaining
patient (nr. 4) developed an unexplained neurological
syndrome accompanied by signs of haemolysis with the
Hb nadir 30 days after starting artesunate treatment.
Also, one patient (nr. 28) experienced persistent haemo-
lysis until 7 weeks after artesunate treatment which
required a total of 7 blood transfusions (Table 6).
For the remaining patients with severe malaria there
were no reports of haemolysis although Hb values in
week 2 were only available for 20 of them. Thus, in the-
ory, the worst case scenario for the frequency of the late
onset haemolysis could be in the order of 6/(20 + 6) =
23% (95% confidence interval 7 to 39%). However, we
feel that, given the conditions in Belgium and the Neth-
erlands, it is unlikely that severe haemolysis would go
unnoticed. There was no difference in median cumula-
tive dose between patients with and without haemolysis
(7.2 vs 7.5 mg/kg resp; p = 0.91).
Discussion
In this study, the Dutch and Belgian experience with the
use of IV artesunate on a named patient basis is presented,
the largest case series of patients with severe malaria in
Europe. Mortality was low and parasite clearance was
rapid. Late onset haemolysis was observed, mostly short
lived, which confirms recent findings in travellers with
severe malaria treated with IV artesunate [7].
In this study, probably all patients treated with artesu-
nate in the Netherlands were captured. The Netherlands is
a small country, the professional groups are well organized
and there is little chance that patients would have been
treated outside our scope. For Belgium, this was different,
only patients from two Belgian hospitals were traceable.
There is no indication of a selection bias towards the use
of artesunate or quinine. Once artesunate was available in
hospitals, this became the drug of choice.
A named patient programme cannot substitute for pro-
spective clinical research. Nevertheless, this type of phar-
macovigilance studies may capture more information
than a prospective clinical trial, especially rare and late
onset events. All treating hospitals are large medical cen-
tres with high quality care, accredited laboratories and
close follow up procedures, ensuring a high reliability
and quality of the data.
A limitation of this retrospective study is the heteroge-
neity of patient characteristics and therapeutic interven-
tions: Twenty-five patients received quinine or other anti-
malarial agents before artesunate, while 17 received
exchange transfusion or erythrocytapheresis. The decision
Table 1 General characteristics on admission
Characteristics Value
Median age (range), y
Adult (n = 65) 46.9 (18.4 - 83.6)
Child (n = 3) 4.8 (2.8 - 5.2)
Men, n (%) 47 (69)
Continent of birth, n (%)
Europe 34 (50)
Africa 27 (40)
Other 7 (10)
Immunity status*, n (%)
Non-immune 39 (57)
Partially immune 29 (43)
Semi immune 0 (0)
Chemoprophylaxis, n (%)
Adequate 1 (2)
Inadequate 58 (85)
Absent 49 (72)
Inappropriate 9 (13)
Unknown 9 (13)
Indication for artesunate, n (%)
Severe malaria
§ (> 1 of the following criteria) 51 (75)
Impaired consciousness 18 (26)
Multiple convulsions (> 2 episodes/24 h) 0 (0)
Respiratory distress or pulmonary edema 4 (6)
Shock (systolic blood pressure < 70 mm Hg) 6 (9)
Haemoglobinuria 2 (3)
Abnormal bleeding 1 (2)
Hypoglycaemia (glucose < 2.2. mmol/L) 1 (2)
Acidaemia (pH < 7.25) 3 (4)
Acidosis (plasma bicarbonate < 15 mmol/L) 4 (6)
Anaemia (Hb < 3.1 mmol/l or haematocrit < 15%) 0 (0)
Hyperparasitaemia (> 5%) 33 (49)
Hyperlactataemia (lactate > 5 mmol/L) 8 (12)
Renal impairment (creatinine > 265 μmol/L) 7 (11)
Jaundice (bilirubin > 50 μmol/L) 24 (35)
Non severe malaria on admission 17 (25)
Clinical deterioration to severe malaria 4 (6)
Parasitaemia between 2-5% 4 (6)
Unable to take oral medication
† 5 (7)
Other
‡ 4 (6)
* estimated as described earlier by Van Genderen et al. 2010 [11] Non-
immune: European travellers and tourists; partially immune: adult immigrants
from a malaria endemic country living in the Benelux; semi-immune: patients
who had been living in a malaria-endemic area for at least 2 years preceding
the time of diagnosis
§ One patient was diagnosed with a mixed infection of P.falciparum and P.
malariae
†One patient was diagnosed with P.ovale, one with P. vivax
‡ One patient was diagnosed with P. vivax
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Characteristic Number of patients (%) Value
Mean weight (SD), kg 53 (78) 73.2 (20)
Mean temperature (SD), °C 60 (88) 38.6 (1.3)
Mean respiratory rate (SD), breaths/min 16 (24) 25 (8)
Mean heart rate (SD), beats/min 64 (94) 106 (18)
Mean systolic blood pressure (SD), mm Hg 63 (93) 115 (19)
Mean diastolic blood pressure (SD), mm Hg 63 (93) 66 (13)
Median parasitaemia (range),% parasitized erythrocytes 68 (100) 5.0 (0.05-37.4)
Median haemoglobin (range), mmol/L 68 (100) 8.0 (3-10.2)
Median haematocrit (range),% 66 (97) 38 (18-50)
Mean erythrocytes (SD), × 10
12 cells/L 51 (75) 4.2 (1.2)
Median leukocyte count (range), × 10
9cells/L 68 (100) 5.2 (2.5-13.2)
Median serum urea (range), mmol/L 66 (97) 10 (2-94)
Median serum creatinine (range), μmol/L 68 (100) 92 (3-1081)
Median total bilirubin (range), μmol/L 60 (88) 42 (0-299)
Median sodium (range), mmol/L 68 (100) 134 (121-146)
Median potassium (range), mmol/L 65 (96) 3.8 (2.7-41.0)
Median glucose (range), mmol/L 61 (90) 6.4(2.0-18.4)
Median pH (range) 35 (51) 7.45 (6.71-7.57)
Median base excess (range), mmol/L 40 (59) 0.8 (-18.0-28.6)
Mean HCO3
- (SD), mmol/L 44 (65) 21.3 (4.9)
Median plasma lactate (range), mmol/L 35 (51) 2.8 (9.0-34.0)
Table 3 Administered treatment
Variable Number of patients (ntotal = 68)
Initial treatment, n (%)
Artesunate 43 (63)
monotherapy 39 (57)
+ clindamycin 2 (3)
+ doxycycline 2 (3)
Quinine 19 (28)
AP 2 (3)
AL 2 (3)
SP + doxycycline 1 (2)
Unknown oral anti-malarial 1 (2)
Artesunate
Median number of doses (range) 3 (1-7)
Median cumulative dose (range), mg 600 (120-1320)
Median cumulative dose/bodyweight (range), mg/kg 7.5 (2.3-18.1)
Oral anti-malarial drug after artesunate, n (%)
AP 41 (60)
AL 20 (29)
Doxycycline 2 (3)
Doxycycline + Quinine 1 (2)
Clindamycin + Quinine 1 (2)
AP + mefloquine 1 (2)
Primaquine 1 (2)
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case management. In Belgium, criteria for administrating
IV artesunate are restricted to patients with ‘very severe
malaria’ and vomiting patients intolerant of IV quinine. In
the Dutch malaria treatment guidelines (’StichtingWerk-
groepAntibioticabeleid’ (SWAB), the Dutch Working
Party on Antibiotics Policy; http://www.swab.nl), artesu-
nate is treatment of choice in severe malaria, however,
when not available, quinine should be administered
instead or until artesunate is available. The availability of
artesunate increased rapidly in the last few years (seven
out of 90 Dutch hospitals had artesunate in stock in 2008,
44 in 2010 (distribution records)), while pre-treatment
with quinine has decreased in the same period.
Although the contribution of exchange transfusion has
been disputed, it accelerates parasite clearance during
quinine treatment [11]. Its benefit during artesunate
treatment needs further study. Nonetheless, Dutch
SWAB guidelines consider exchange transfusion in
patients with > 10% parasitaemia or severe illness with
organ failure. In Belgium, erythrocytapheresis was the
standard procedure in patients with very high parasitae-
mia (> 15%) until IV artesunate became available. Since
then, it has been largely abandoned.
The cure and survival rates among patients with
severe malaria in the present study were high. The
death of the two patients was not directly related to
malaria and/or the treatment with artesunate. Although
sample size of the present study is small and although it
i si n a p p r o p r i a t et oi n f e rt h ee v i d e n c ef r o me n d e m i c
regions [2,3] and the treatment outcome of quinine in
French malaria patients to the present population, it
confirms what has been stated before; IV artesunate is
an excellent drug for severe malaria, also under the
resourceful conditions of case management in the Neth-
erlands and Belgium.
It has been discussed whether the evidence from
endemic regions can be generalized to the European
population. Patients characteristics, clinical manifesta-
tions and supportive care may differ greatly between
developing and industrialized countries [12]. It has also
been debated whether this would justify or even require
a trial comparing artesunatea n dq u i n i n ef o rE u r o p e a n
patients. Our current view is that severe malaria is such
Table 3 Administered treatment (Continued)
Mefloquine 1 (2)
Supportive care, n (%)
Erythrocytapheresis 4 (6)
Exchange transfusion 13 (19)
Blood transfusion 9 (13)
Platelets transfusion 1 (2)
Mechanical ventilation 6 (9)
Haemodialysis 5 (7)
AP: atovaquone-proguanil; AL: artemether-lumefantrine; SP: sulphadoxine-pyrimethamine;
Before receiving artesunate, 25 patients (37%) received another anti-malarial drug. The median number of IV dosages of artesunate was 3 (range 1-7) doses. The
median cumulative artesunate dose was 600 mg (range 120-1320 mg) or 7.5 mg/kg (range 2.3-18.1) mg/kg. The median time between diagnosis of malaria and
first dose of artesunate was 4.0 hours (range 0-47 hours). Treatment was changed to oral anti-malarial drugs after a time of 2 days (range 0-6 days) after first
dose of artesunate. The majority received either AP (60%) or AL (29%).
Table 4 Outcome
Endpoint Number of patients
(n = 68)
Mortality, n (%)
among severe malaria,% (n = 55) 2* (3.6)
Mean parasite clearance times (95% CI),
hours
†
PCT50% 4.4 (3.9 - 5.2)
PCT90% 14.8 (13.0 - 17.2)
PCT99% 29.5 (25.9 - 34.4)
ICU admittance, n (%) 42 (62)
Median duration of ICU stay (range), days 2 (1-35)
Median duration of hospital stay (range),
days
4.5 (1-76)
PCT50%, PCT90%, and PCT99% are the parasite clearance times, defined as
the time (in hours) to obtain a 50%, 90%, and 99% reduction in parasite
count after start of artesunate treatment, respectively
* One patient still suffered from a delirious state and in an unobserved
moment he inadvertently removed his haemofiltration catheter from the
femoral vein. He died due to a loss of blood. A second patient died shortly
after sudden collapse during defecation and pulmonary embolism was
suspected but not confirmed as autopsy was not permitted. It occurred while
the patient was treated with subcutaneous low molecular weight heparin
† Calculated from 57 patients with the following conditions:
■ the limit of detection was set at 10 parasites/μL. Non detectable parasite
counts were not included in the log linear effects model
■ when more than one slide was made before artesunate treatment was
given, the oldest slides were excluded from analysis. The value nearest to T0
was used
■ for repeated parasite counts around the detection limit, only the first value
was included in the model
■ Malaria cases caused by other species than P. falciparum were excluded for
estimation of parasite clearance rates
■ In most patients (88%) parasite counts were performed at least twice in the
first 24 hours (range 1-7 times)
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Complication Number of patients (%) Recovery*
Haematological, n (%)
Abnormal bleeding 1 (2) Recovered
Anemia 32 (47)
hemolytic
† 7 (10) Recovered in all
severe (Hb< 3.6 mmol/l) 2 (3) Recovered in all
moderately severe (3.7 - 6.1 mmol/l) 23 (34) Recovered in 11/11
‡
Thrombocytopenia (< 20 giga/L) 16 (24) Recovered in all
Hemoglobinuria 1 (2) Recovered
Hepatobiliary, n (%)
Elevated liver enzymes (LDH > 2x URL) 31 (46) Recovery in 14/14
‡
Renal, n (%)
Acute renal insufficiency 7 (10) Recovered in 5/5
‡
Acute tubular necrosis 1 (2) Recovered
Anuria 1 (2) Not resolved, still in need of dialysis
Elevated creatinine levels (> 20% above URL) 9 (13) Recovered in 4/4
‡
Nervous system, n (%)
Anal sphincter dysfunction 1 (2) Recovered
Aphasia 1 (2) Recovered
Cerebral edema 1 (2) Recovered
Coma 2 (3) Recovered
Convulsion 3 (4) Recovered
Delirium 2 (3) Recovered in 1/2
§
Diplopia 1 (2) Restoring but lost to follow up
Neurological deficit 1 (2) Recovered
Truncal ataxia 1 (2) Restoring but lost to follow up
Cardiovascular, n (%
Arterial hypertension 1 (2) Recovered
Atrial flutter 2 (3) Recovered
AV Block (1
st degree) 1 (2) Recovered
Prolonged QTc interval 1 (2) Recovered
Sinus bradycardia 1 (2) Recovered
║
Supraventricular tachycardia 1 (2) Recovered
Thrombophlebitis 2 (3) Recovered
Respiratory, n (%)
Exercise induced dyspnea 1 (2) Recovered
Pneumonia 4 (6) Recovered
Respiratory insufficiency 4 (6) Recovered
Other, n (%)
Deafness 3 (4) Recovered in 2/3
¶
Diarrhoea 3 (4) Recovered
Fever 1 (2) Recovered
Furunculosis 1 (2) Recovered
Hypoglycaemia 1 (2) Recovered
Peri-anal abcess 1 (2) Recovered
Rash 2 (3) Recovered
Reactive arthritis 1 (2) Recovered
Sepsis 1 (2) Recovered
Kreeftmeijer-Vegter et al. Malaria Journal 2012, 11:102
http://www.malariajournal.com/content/11/1/102
Page 7 of 11a rare disease in Europe that sufficient sample sizes can-
not be obtained. Furthermore, the question remains
whether European physicians would be willing to parti-
cipate in such a trial now that artesunate is recom-
mended as the treatment of choice for severe malaria by
WHO [9].
Severe post-treatment haemolysis occurred unexpect-
edly in seven patients. This was also observed in 24% of
patients treated with IV artesunate in another study [7]
in which post-treatment haemolysis was associated with
higher doses of artesunate and longer treatment periods.
This was not observed in the present study. Four
patients received AL as a consolidation treatment. Arte-
mether but also lumefantrine or quinine may induce
haemolysis (’blackwater fever’) [13,14].
Surprisingly, in the SEAQUAMAT and AQUAMAT
trials [2,3], over 3000 patients were treated with IV arte-
sunate, even with higher cumulative doses of artesunate
than in the present study, and often also with AL, but
no haemolysis was reported. These trials were not
designed to capture this late onset event.
In acute falciparum malaria, anaemia and prolonged
haemolysis may persist for weeks after elimination of
parasites, regardless the treatment given [15,16]. Other
factors could also have contributed to the haemolysis.
For example, one patient was heterozygous for glucose-
6-phosphate dehydrogenase (G6PD) deficiency. Three
patients received exchange t r a n s f u s i o ni nc o n j u n c t i o n
with anti-malarial treatment. Furthermore, both positive
(3 times) and negative (3 times) direct Coombs test
results were observed. Anti-erythrocyte antibodies can
be secondary to malignancies, autoimmune disorders,
transfusion reactions and also to drugs [17] and is rather
common after malaria [18]. Drug induced haemolysis
with a negative direct Coombs test has also been docu-
mented [19].
Since physicians were not alerted to this phenomenon,
additional investigations were not performed. It is there-
fore difficult to assess whether exposure to artesunate
was the sole cause. Moreover, the causality of artesunate
administration is not easily established by using adverse
drug reaction scales, mainly because scores on these
scales are largely affected by the relationship in time
between drug administration and onset of the adverse
event [20]. The haemolysis started long after complete
clearance of artesunate [21]. There are several effects of
artesunate on cellular biology, including suppressive
effects on erythropoiesis and angiogenesis [22]. Recently
Berdelle and colleagues demonstrated that artesunate
has mutagenic potential [23]. Whether these effects
extend to a-nuclear erythrocytes is not known. Another
explanation of late onset hemolysis could be a reduced
survival of ‘pitted’ infected erythrocytes [24,25]. This
would explain the fact that in this study haemolysis was
only seen in patients with very high parasitaemia (11-
37%). This is refuted by the fact that not all patients
with high parasitaemia develop late onset haemolysis.
Moreover, a similar type of hemolysis was also observed
in a patient with non-hyperparasitaemic non-severe
malaria, treated with AP followed by AL (unpublished
data). Whatever the mechanism, a weekly follow up for
4 weeks with Hb measurement and, if not improving,
also other parameters of haemolysis, should be per-
formed. More importantly, as the majority of parasites is
cleared within 24 hours, and in light of the possible role
of artesunate in the development of late onset haemoly-
tic anaemia, the authors would like to recommend to
limit treatment to the period that IV treatment is
deemed necessary. In practice this is no longer than 48
hours. Treatment should be followed by an adequate
and full course of oral anti-malarial treatment.
There is still no marketing authorization for an artesu-
nate product on the European market. This is due to
the fact that it is challenging to develop a suitable for-
mulation that meets the requirements of GMP. Several
companies are currently working on GMP-conform IV
artesunate formulations, while others work on semi-syn-
thetic production of artemisinins [26,27]. Importing
drugs into Europe is subject to strict regulations, which
ensure that patients would never receive a non-properly
tested and released product. There are several compa-
nies involved in importing artesunate into Europe.
Conclusions and recommendation
The excellent efficacy of IV artesunate for severe
imported malaria in industrialised countries supports
Table 5 Complications (Continued)
Tropical ulcers 1 (2) Recovered
URL: Upper reference limit reported by laboratory of admitting hospital
* Number of patients that completely recovered/number of patients of whom data was complete (adequate follow up)
† characterized by increased reticulocyte counts, unconjugated bilirubin and lactate dehydrogenase and decreased haptoglobin and haemoglobin (Hb) values.
See Table 6 for further details
‡ complication restoring in the remaining patients but patients were not followed until complete recovery (incomplete data)
§ the other patient died
║ patient received pacemaker
¶right ear remains deaf in one patient
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Page 8 of 11Table 6 Haemolysis in 7 hospitalized malaria patients receiving IV artesunate treatment
Patient
(gender,
age)
Severe malaria
criteria
Anti-malarial
treatment
PCT
(days)
*
Hb
nadir
(days)*
Additional
diagnostics
Treatment for
haemolysis
Late onset hemolysis
1( ♂, 53y) Hyperparasitaemia (34%), impaired consciousness, jaundice Q
AS (2 doses)
AP
AET
4 4.3 (D20) Coombs: C3d+ None
4( ♀, 50y) Hyperparasitaemia (19%), impaired consciousness, jaundice, acidosis,
hyperlactaemia, renal impairment
AS (4 doses)
AP
MET
3 4.4 (D30) Multiple in the context of an unexplained
neurological disorder
‡; coombs not performed
None
38 (♀, 50y) Hyperparasitaemia(11%), jaundice AS (4 doses)
AP
3 2.8 (D13) Coombs: neg; G6PD deficient (heterozygous);
Shigellaflexneri dysentery
Transfusion(4 PC)
55 (♀, 44y) Hyperparasitaemia
(37%)
Q
AS (3 doses)
AL
4 3.8 (D15) Coombs: IgG +, C3d+ Transfusion(2 × 3
PC)
Steroids
58 (♂, 5y) Hyperparasitaemia (12%), impaired consciousness, shock Q
AS (doses)
AL
4(FCT
10 d)
3.8 (D8) Coombs: neg; hemoculture - None
59 (♀, 50y) Hyperparasitaemia (30%), hemoglobinuria, jaundice AS (doses)
AL
10
(FCT
17 d)
4.3 (D13) Coombs: IgG+, IgM+,
hemoculture -
G6PD: normal
Transfusion (2 PC)
Steroids
Persistent hemolysis
28 (♂, 71y) Hyperparasitaemia (20%), impaired consciousness, respiratory distress,
acidosis, hypoglycaemia, hyperlactaemia, renal impairment
Q
AS (doses)
AL
AET
7
† 3.7 (D13) Coombs: neg Transfusion (7
times, total of 24
PC)
Q: quinine, AS: artesunate, AP: atovaquone-proguanil AL: artemether-lumefantrine, AET: automated exchange transfusion, MET: manual exchange transfusion, PCT: parasite clearance time; FCT: fever clearance time;
neg: negative; G6PD: glucose-6-phosphate dehydrogenase; HC: hemoculture; PC: packed red cells; CS: corticosteroids
* number of days after 1
st artesunate gift
† Parasitological examination was not performed between day 3 and 6 after first artesunate gift. On day 7, malaria slides were negative
‡ Hospital stay was complicated with disorientation for which patient was treated with haloperidol. Patient left the hospital against medical advice on Day 5 while not recovered fully. Within 4 weeks she was
readmitted with an overt status epilepticus and fever. Diazepam, propofol and phenytoin were given after which the epileptic activity ceased. She was intubated and mechanically ventilated for 3 days. An extensive
search for infectious (malaria, Epstein-Barrvirus, cytomegalovirus, Herpes simplex virus, Varicella zoster virus, enterovirus, parechovirus) and metabolic causes remained negative. Cerebrospinal fluid culture was
negative. MRI of the brain showed diffuse cortical edema and no other abnormalities. She was treated with methylprednisolone after which she started to recover
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1the efforts to make this drug available throughout Eur-
ope. The roll-out of IV artesunate should be closely
monitored by a pharmacovigilance programme, such as
was set up for this study. Meanwhile, increased safe-
guards with respect to haematological abnormalities
should be instituted in the follow-up period after anti-
malarial treatment at least once weekly until 4 weeks
after initiation of therapy. The fast clearance of parasites
warrants the reduction of the length of treatment with
artesunate. The authors woul d ,t h e r e f o r e ,r e c o m m e n d
Figure 1 Haemoglobin values of patients with haemolysis after being treated for severe malaria with IV artesunate.
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Page 10 of 11that treatment with artesunate should be limited to the
period that IV treatment is required and should be fol-
lowed by a full oral course of an appropriate anti-malar-
ial drug.
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